Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Clinical trial NCT05755087 · RECRUITING

Trial details

NCT number: NCT05755087
Sponsor: Lapo Alinari
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Start date: 2023-03-06
Primary completion: 2028-03-05
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.